Pune | Oct 8, 2025, 18:00 IST — Enzene Biosciences Ltd, a leading biologics CDMO (Contract Development & Manufacturing Organization), today announced it has become the first Indian company to deploy Virtuosi®, an AI-powered immersive training platform for pharmaceutical manufacturing, particularly in bioprocess disciplines.
The collaboration positions Enzene at the cutting edge of workforce development in India’s biologics sector, giving it access to advanced training modules in areas such as aseptic processing, microbiology, quality assurance, data integrity, and regulatory compliance.
What is Virtuosi® & Why It Matters
Virtuosi®, developed by Quality Executive Partners (QxP), is an interactive training platform accredited by IACET that combines virtual reality, digital simulation, and expert-led curricula specifically for pharmaceutical manufacturing. The platform includes modules on sterility assurance, cell & gene therapy manufacturing, and microbiology operations.
The goal is to reduce the time to competency and minimize human error — two critical challenges in bioprocess operations where mistakes can be costly in time, material, or regulatory compliance.
By adopting Virtuosi®, Enzene aims to upskill its workforce to global standards — ensuring staff are trained in advanced methods even before they operate real equipment or work in GMP environments.
Enzene’s Motivation & Strategic Fit
Enzene describes itself as a “fully integrated, end-to-end continuously innovative development and manufacturing organization (CIDMO).” Its facilities in Pune are already EU-GMP certified for mammalian and microbial biologics manufacturing.
In a statement, Dr. Sundar Ramanan, Chief Quality Officer at Enzene, said:
“By partnering with Virtuosi, we are investing not only in training excellence for our own teams but also setting a benchmark for the entire industry. This is about raising the standard for how medicines are made — safely, compliantly, with world-class technical mastery.”
Meanwhile, Crystal Mersh, CEO & Founder of Quality Executive Partners, noted that Enzene’s adoption is a signal that India’s bioprocess industry is evolving beyond capacity build-up toward capability enhancement:
“As the first global company to implement Virtuosi in India, Enzene signals a new era of manufacturing excellence … showcasing that India’s CIDMO sector is not only scaling capacity, but also investing in the people and knowledge needed to sustain excellence.”
Implications for India’s Biologics & CDMO Sector
- Talent readiness
The biologics sector is highly specialized; having a trained workforce ready from day one is essential. Virtual training helps close the skill gap, especially in newer biotech cities where local experience may be scarce. - Scalable & safe training
Traditional on-the-job training in bioprocess and aseptic operations is expensive and fraught with risk. Virtuosi allows simulation at scale without consuming reagents or risking contamination. - Regulatory alignment
As India aims to capture a larger share in global biologics manufacturing, meeting international training, quality, and regulatory standards becomes essential. Advanced training platforms help support that compliance posture. - Competitive differentiation
For Enzene, deploying Virtuosi may offer a differentiation: not just as a manufacturer but as a training and capability leader. This could help attract clients who want quality assurance across the supply chain.
Challenges & Considerations
- Adoption & integration: Deploying an advanced training system is one thing; integrating into daily operations, ensuring uptake, and measuring ROI are more complex tasks.
- Cultural shift: Not all staff may initially embrace virtual/VR training; change management will be required.
- Cost & access: Licenses, software updates, hardware (VR headsets), and content localization may impose costs.
- Validation & regulatory acceptance: Regulators may need evidence that VR/simulation training translates into real-world performance and compliance.
What to Watch
- Expansion plans: Whether Enzene deploys Virtuosi across all its sites (India + U.S.) or offers training services to peers.
- Client onboarding: If clients begin to request or require such training credentials as part of supplier evaluation.
- Content evolution: Whether new modules—for advanced biologics, cell & gene, gene-editing bioprocesses—are added.
- Performance metrics: Time-to-proficiency, error reduction, regulatory audit findings, and training ROI will be key indicators.
Why It Matters: India’s biologics & CDMO sector is rapidly growing, but its strength hinges not just on capacity expansion but on talent, quality, and regulatory resilience. Enzene’s move to adopt Virtuosi® is a signal that India’s pharma manufacturing is investing in human capital with future-ready tools.
